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Abstract
The synthesis of the recently characterized depsipeptide szentiamide (1), which is produced by the entomopathogenic bacterium
Xenorhabdus szentirmaii, is described. Whereas no biological activity was previously identified for 1, the material derived from the
efficient synthesis enabled additional bioactivity tests leading to the identification of a notable activity against insect cells and
Plasmodium falciparum, the causative agent of malaria.
Introduction
Bacteria of the genus Xenorhabdus live in symbiosis with
nematodes of the genus Steinernema and together they form an
entomopathogenic complex that can infect and kill several
insect larvae. During this complex life cycle the bacteria
produce secondary metabolites, which may be involved in and/
or may be required for different stages of this life cycle,
including the symbiotic stage (towards the nematode) or patho-
genic stage (towards the insect prey) [1-3]. Until three years
ago, the natural products extracted from Xenorhabdus and its
close neighbour Photorhabdus were only low-molecular-weight
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Scheme 1: Overview of the synthetic strategy.
compounds with UV chromophores (e.g., isopropylstilbenes [4],
anthraquinones [4], or xenorhabdines [5]. However, bioactivity-
based or MS-based screening of crude extracts and culture
supernatants led to the identification of larger compounds, such
as the PAX peptides [6], the xenortides [7], xenematide [8] and
the GameXPeptides [9]. Analysis of the genome sequences of
the ful ly sequenced members of  Xenorhabdus  and
Photorhabdus [10,11] has revealed that several additional com-
pounds and especially even much larger compounds await isola-
tion and structure elucidation. Recently, szentiamide (1) has
been isolated, representing only the second depsipeptide
(Figure 1) from these bacteria [12]. It is composed of six amino
acids having a formylated N-terminus and raised our interest as
it is produced by X. szentirmaii, whose crude extract shows a
very high biological activity in several different bioassays
(unpublished data). Nevertheless, no bioactivity has been
described for 1 so far. Since we believe that 1 must have a bio-
logical function that is simply awaiting its identification, and
since the peptide can only be found in small amounts when X.
szentirmaii is grown in Luria–Bertani media, we wanted to
synthesize it and make it accessible for additional bioactivity
tests.
Results and Discussion
Synthesis
As previous syntheses of depsipeptides showed that lactamiza-
tion was preferred over lactonization [13,14], the synthesis of 1
was performed as follows: briefly, the linear peptide was
synthesized using solid-phase peptide synthesis, followed by
esterification and subsequent cleavage from the resin, deprotec-
Figure 1: Structure of depsipeptides szentiamide (1) [12] and xene-
matide (2) [8] identified in Xenorhabdus strains.
tion and cyclization to yield 1, assisted by microwave irradi-
ation at every stage with the exception of the esterification
(Scheme 1).
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Scheme 2: Synthesis of compound 1.
In detail, a preloaded 2-chlorotrityl chloride resin was used in
order to avoid nonspecific interaction in the cyclization process.
Prior to the synthesis, the resin was reactivated [15] and then
loaded with Fmoc-L-Tyr(t-Bu)-OH [16], followed by the build-
up of the linear sequence 3 (Scheme 2) with O-benzotriazole-
N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) in
dimethylformamide (DMF) and N,N-diisopropylethylamine
(DIEA) in N-methylpyrrolidone (NMP), assisted by microwave
irradiation. After the final Fmoc-deprotection with 20% piperi-
dine in DMF, the N-terminus was formylated with para-nitro-
phenyl formate (pNPF) in the presence of N-methylmorpholine
(NMM) at 4 °C, affording the synthetic intermediate 4.
The attempts to form the ester bond by using catalytic amounts
of 4-dimethylaminopyridine (DMAP) with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), DMAP together
with N,N′-diisopropylcarbodiimide (DIC), or a mixture of the
DMAP hydrochloride and DMAP together with DIC all turned
out to be unsuccessful. However, we were then able to estab-
lish the ester bond in 5 using modified Yamaguchi conditions
[17]. Subsequently, the Fmoc-protecting group was removed at
room temperature, and the peptide was cleaved from the resin
with 3% hexafluoroisopropanol (HFIP) in dichloromethane
(DCM) in order to preserve the side-chain protecting group.
Following this, the peptide was cyclized in solution by using
O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexa-
fluorophosphate (HATU) and DIEA in DMF, assisted by
microwave irradiation. Afterwards, the remaining side-chain
protecting group was removed by incubation with a common
cleavage cocktail for 60 min at room temperature to give the
crude product 1, which was purified by preparative reversed-
phase HPLC (yield: 14% from the resin (B = 0.84 mmol/g)). In
order to compare the synthetic to the natural product we isolated
1 from Xenorhabdus szentirmaii DSM 16338 as described
previously [12]. Briefly, the strain was cultivated in a shake
flask containing Luria–Bertani media and 2% Amberlite XAD-
16 adsorber resin. After cultivation for three days at 30 °C, the
resin was collected and the bound substances were eluted with
methanol (MeOH) repeatedly. The resulting brown, oily crude
extract was fractionated by normal-phase flash chromatography,
followed by the isolation of compound 1 by preparative
reversed-phase HPLC. In contrast to already published data [12]
we were able to isolate 26.8 mg from a 2 L culture, which
corresponds to a yield of 0.015 % (m/v). Thus, the addition of
Amberlite XAD-16 adsorber resin led to a 150-fold increase of
the production of 1 in comparison to cultures cultivated without
XAD-16 [12]. In fact the productivity was even higher, since it
was obtained from a three-day instead of the described eight-
day cultivation of X. szentirmaii. Comparison of the LC–MS
(Figure 2b and c) and NMR data (Figure S1, S2 and Table S1 in
Supporting Information File 1) proved the synthetic 1 to be
identical to the natural product.
Biological testing
The cyclic depsipeptide 1 was tested against different Gram-
positive (Micrococcus luteus, Bacillus subtilis, Staphylococcus
aureus) and Gram-negative (Escherichia coli, Pseudomonas
aeroginosa) bacteria, as well as yeast (Candida albicans,
Saccharomyces cerivisiae). However, consistent with the
published data [12], no antibacterial or antifungal activity was
detected. Additionally, the peptide 1 was tested against several
parasites (Trypanosoma brucei rhodesiense, Trypanosoma
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Figure 2: HPLC–MS data of an XAD-extract of X. szentirmaii (a; base-
peak chromatogram), the natural 1 (b; extracted-ion chromatogram)
and synthetic 1 (c; extracted-ion chromatogram) with their MS2-spectra
(d, natural 1, and e, synthetic 1).
cruzi, Leishmania donovani, Plasmodium falciparum) being the
causative agents of the neglected tropical diseases [18] sleeping
sickness, leishmaniasis and malaria. Interestingly, a good
activity against the malaria-causing parasite P. falciparum
(IC50 = 0.995 µg/mL) was observed, but only a 50- to 80-fold
weaker cytotoxicity (L6 cells, IC50 = 57.4 µg/mL and
HeLa cells, IC50 > 80 µg/mL). Only a weak activity was
observed against T. b. rhodesiense and L. donovani with
IC50 = 10.0 µg/mL and IC50 = 11.0 µg/mL, respectively. Addi-
tionally, we also tested 1 against hemocytes of Galleria
mellonella and could detect a LD50 value of 59.7 µg/mL.
Conclusion
The establishment of an efficient synthesis route for the
depsipeptide szentiamide (1) from X. szentirmaii revealed its
biological activity against insect cells and protists such as
P. falciparum. The rationale behind this bioactivity may be that
1 adds to the overall insecticidal activity of Xenorhabdus
bacteria. Protists such as amoeba are common soil inhabitants,
which may feed on the dead insect cadaver. Thus, compounds
such as 1 may protect the insect cadaver against these food
competitors and “accidentally” may also target pathogenic
protists such as Plasmodium, which is a global human threat.
Therefore, the bioactivity of 1 revealed in this study highlights
the potential of Xenorhabdus bacteria as producers of bioactive
natural products and the importance of a broad bioactivity
testing of isolated compounds in order to find a biological
activity and thus a biological function of such natural products.
Work in the Bode lab currently concentrates on the identifica-
tion of the mode of action of 1 in insects and protists in order to
also understand its molecular function.
Experimental
Synthesis
Unless otherwise stated, we used the chemicals in their highest
available purity. The progress of the synthesis was monitored
with MALDI–MS as well as RP-UPLC coupled with ESI–MS.
Solid-phase peptide synthesis. The linear sequence was
synthesized on a preloaded 2-chlorotrityl chloride resin (Carbo-
lution Chemicals, Germany) on a 50 μmol scale with the
Discover CEM System by using standard 9-fluorenylmethoxy-
carbonyl/tert-butyl (Fmoc/t-Bu) chemistry. An amount of
6 equiv of amino-acid derivatives (>98%; Iris Biotech,
Germany/Carbolution Chemicals; c = 0.2 mol/L) was activated
in situ with 5 equiv O-benzotriazole-N,N,N′,N′-tetramethyluro-
nium hexafluorophosphate (HBTU; Iris Biotech) in dimethyl-
formamide (DMF; Acros Organics, Belgium; c = 0.5 mol/L) in
the presence of 10 equiv N,N-diisopropylethylamine (DIEA;
Novabiochem, Darmstadt, Germany) in N-methylpyrrolidone
(NMP; VWR, Germany; c = 2 mol/L). Fmoc protecting groups
were cleaved with 20% piperidine in DMF by using microwave
irradiation as well.
Formylation. The free N-terminus was formylated with 5 equiv
para-nitrophenyl formate (pNPF; Sigma Aldrich, Germany) and
3 equiv N-methylmorpholine (NMM; Sigma Aldrich, Germany)
in DMF (c = 12.5 mmol/L) at 4 °C over night.
Ester bond formation. The depsipeptide bond was formed by
using 20 equiv Fmoc-protected amino acid, 20 equiv benzoyl
chloride (BzCl, Sigma Aldrich, Germany) and 40 equiv (Et3N,
Sigma Aldrich, Germany) in DCM (c = 62.5 mmol/L) first at
0 °C then with warming to room temperature overnight. After
the quantitative reaction, the Fmoc-protecting group was
cleaved by using 40% piperidine in DMF for 2 min and then
20% piperidine in DMF for 10 min at room temperature.
Cleavage and cyclization. The protected branched peptide was
cleaved with 3% hexafluoroisopropanol (HFIP; Carbolution
Chemicals, Germany) in dichloromethane (DCM; VWR,
Germany) and cyclized in solution (20 min, 25 W; 75 °C) by
using O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluro-
nium hexafluorophosphate (HATU; Carbolution Chemicals,
Germany) and DIEA in DMF (c = 4 mmol/L). The cyclized
product was fully deprotected by incubation with 95% trifluo-
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roacetic acid (TFA; Iris Biotech, Germany) and 2.5% triiso-
propylsilane (TIPS, Alfa Aesar, Germany) in deionized water at
room temperature for at least 60 min. Then the cleavage cock-
tail was evaporated and the peptide dissolved in MeOH in order
to purify it by HPLC–MS (Waters® PurificationTM System,
Waters Corporation, USA; Jupiter Proteo, Phenomenex,
Germany). The purity was determined by RP-UPLC coupled
with ESI–MS.
Fermentation. Xenorhabdus szentirmaii was cultivated at
30 °C and 280 rpm on a rotary shaker in two 5 L Erlenmeyer
flasks each containing 1 L of Luria–Bertani (LB) broth (pH 7.0)
and 2% (v/v) of XAD-16 (Sigma-Aldrich, Germany). These
cultures were inoculated with 1% (v/v) of an 18 h preculture in
the same medium without XAD-16. Cultures were harvested
after three days, and XAD beads were separated from the super-
natant by sieving.
Isolation. After washing with H2O the XAD beads where
extracted with MeOH (2 × 50 mL), followed by concentration
to dryness under reduced pressure, yielding a brown oily
residue and amorphous precipitate. This was dissolved in 4 mL
MeOH, centrifuged for 10 min and 13000 rpm at room tempera-
ture and the pure compound isolated from the supernatant by
HPLC-MS.
Biological testing
Disk diffusion Test. The nonpathogenic strains E. coli BL21,
M. luteus, B. subtilis and S. cerevisae PK113 were cultured
overnight at 30 °C in LB and YPD media. Agar plates were
overlaid with an inoculum (turbidity equivalent to the optical
density of 0.5 measured at 600 nm) of the different strains.
Cellulose disks (100% cotton linter; Carl Roth, Karlsruhe,
Germany) were loaded with 100 µg of the peptide. The dried
disks were applied to the prepared agar plates and incubated for
24 h. Then the inhibition zones were measured following
NCCLS criteria [19].
Hemocyte cytotoxicity analysis [20]. Last instar Galleria
mellonella (Greater wax moth) larvae (Livefoods, UK) were
anaesthetized by chilling on ice for 30 min. The larvae were
surface sterilized with 70% ethanol before one of the first
prolegs was excised with micro-scissors. Approximately 1.5 mL
of out-flowing hemolymph was collected from the larvae
directly into 10 mL chilled supplemented Graces Insect
Medium (GIM) (Gibco, Invitrogen) and mixed rapidly by inver-
sion. The hemocyte suspension was then centrifuged at 200 g
for 5 min, the supernatant aspirated and the hemocyte pellet
gently resuspended in 1 mL GIM before being made up to a
final 10 mL dilution. The hemocyte suspension was arrayed into
black microplates (Greiner microclear) and then incubated at
28 °C undisturbed for 60 min to allow the cells to settle and
adhere. The monolayers were washed with GIM before the ad-
dition of GIM containing 100, 10 or 1 µg/mL of each of the
compounds, which were co-incubated with the hemocytes for
4 h. Following incubation, the GIM and compounds mixture
was aspirated and replaced with GIM containing 500 nM Mito-
tracker CMH2XRos for 45 min at 28 °C (Molecular Probes,
Invitrogen). Hemocyte monolayers were washed with 1× PBS
and fixed with 4% paraformaldehyde for 15 min before perme-
abilizing with 0.2% Triton X-100 in PBS for 10 min. Cells were
stained with FITC-conjugated phalloidin and Hoechst 33258
and finally washed with PBS. The plate was imaged by using
the IN Cell Analyzer 2000 (GE Healthcare) and analyzed with
the IN Cell Analyzer 1000 Workstation software. Estimates of
LD50 values were calculated by using the R statistical package
[21].
Cell viability assay. HeLa cells: The water-soluble tetra-
zolium-1 salt (WST-1; Roche Diagnostics, Germany) was used
to determine the cell viability after treatment of cells with the
compounds. HeLa cells were seeded at a density of 3 × 103 cells
in 100 µL culture medium containing 10% FCS into 96-well
microplates and incubated for 24 h at 37 °C. The medium was
removed and HeLa cells were treated with increasing concentra-
tions of the compound (10, 50 and 100 µM) or dimethyl
sulfoxide. After 24 h, 10 µL of WST-1 reagent was added to
each well and the cells were incubated for a further 90–150 min.
The formation of the formazan was measured at 450 nm against
a reference wavelength of 620 nm by using a 96-well spec-
trophotometric plate reader (SpectraFluor Plus, Tecan, Crail-
sheim, Germany). L6-cells: Assays were performed in 96-well
microtiter plates, each well containing 100 μL of RPMI 1640
medium supplemented with 1% L-glutamine (200 mM) and
10% fetal bovine serum, and 4 × 104 L6 cells (a primary cell
line derived from rat skeletal myoblasts). Serial drug dilutions
of seven three-fold dilution steps, covering a range from 90 to
0.123 μg/mL, were prepared. After 72 h of incubation, the
plates were inspected under an inverted microscope to assure
growth of the controls and sterile conditions, 10 μL of Alamar
Blue solution was then added to each well and the plates were
incubated for another 2 h. Then the plates were read with a
Spectramax Gemini XS microplate fluorometer with an excita-
tion wavelength of 536 nm and an emission wavelength of
588 nm. Data were analysed by using the microplate-reader
software Softmax Pro.
Activity testing against parasitic protozoa. Bioactivity
against the four protozoan parasites P. falciparum (NF54),
T. cruzi (Tulahuen C4), T. b. rhodesiense (STIB900), and
L. donovani (MHOM-ET-67/L82) was determined as previ-
ously described [22].
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Supporting Information
Supporting Information File 1
NMR-data of szentiamide (1).
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-8-60-S1.pdf]
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